Facing a perfect storm of disappointing weight‐loss drug sales and investor unease, Novo Nordisk has dramatically downgraded its future forecasts. The fallout has triggered a record plunge in shares while industry watchers and investors scrutinize how the pharmaceutical giant plans to navigate these choppy waters amid high-stakes market expectations.
Back to Top / Tuesday, July 29, 2025, 8:20 am / permalink 11122 / 1 stories in 7 months
Block Inc. Stock Slide Reflects Earnings Disappointment / 10 months
Navan IPO filing reveals steady revenue amid persistent losses / 5 months
CoreWeave Earnings Report: Losses Widen Despite Strong Revenue / 6 months
Bank of America Earnings Show Mixed Financial Signals / 7 months
Lululemon shares plunge amid revised guidance and growth fears / 9 months
UnitedHealth CEO Exit Sparks Forecast Suspension Drama / 9 months
Coinbase Q1 Earnings Show Revenue Slip Amid Investor Disquiet / 9 months
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.